SCHEMBL2736380

SCHEMBL2736380

CC(C)(C)Cc1nc(C(C)(C)C)cs1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR1A P08908 1/20 0.41
HTR2A P28223 1/20 0.41
HTR7 P34969 1/20 0.41
ALDH1A1 P00352 4/20 0.40
CCR4 P51679 6/20 0.40
LMNA P02545 3/20 0.39
TSHR P16473 2/20 0.36
TP53 P04637 1/20 0.36
STAT1 P42224 1/20 0.36
ATAD2 Q6PL18 1/20 0.35
SMN1; SMN2 Q16637 3/20 0.35
HPGD P15428 2/20 0.35
MEN1 O00255 3/20 0.34
KMT2A Q03164 3/20 0.34
POLB P06746 2/20 0.34
NPC1 O15118 2/20 0.34
MAPK1 P28482 2/20 0.34
RAB9A P51151 2/20 0.34
TAS1R3 Q7RTX0 1/20 0.34
TAS1R1 Q7RTX1 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13021191 0.84 LMNA (0.39) ALDH1A1LMNATP53SMN1; SMN2HPGD
SCHEMBL13021199 0.81
SCHEMBL2608448 0.81 LMNA (0.43) HTR1AHTR2AHTR7ALDH1A1CCR4
SCHEMBL5908628 0.79 HTR1A (0.41) HTR1AHTR2AHTR7ALDH1A1CCR4
SCHEMBL5775322 0.79 HTR1A (0.41) HTR1AHTR2AHTR7ALDH1A1CCR4
SCHEMBL4573687 0.79 HTR1A (0.41) HTR1AHTR2AHTR7ALDH1A1CCR4
SCHEMBL19863776 0.78 ALDH1A1 (0.42) HTR1AHTR2AHTR7ALDH1A1CCR4
SCHEMBL2760198 0.78 HTR2A (0.40) HTR1AHTR2AHTR7ALDH1A1CCR4
SCHEMBL10109754 0.77 SMN1; SMN2 (0.41) ALDH1A1SMN1; SMN2MEN1KMT2ANPC1
SCHEMBL21325318 0.77 CCR4 (0.43) ALDH1A1CCR4CNR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10030016-B2 Heterocyclic compounds useful as PDK1 inhibitors SUNESIS PHARMACEUTICALS, INC. (US) 2018-07-24 US disclosed
US-9546165-B2 Heterocyclic compounds useful as PDK1 inhibitors SUNESIS PHARMACEUTICALS, INC. (US) 2017-01-17 US disclosed
US-20160331756-A1 HETEROCYCLIC COMPOUNDS USEFUL AS PDK1 INHIBITORS OXFORD FINANCE LLC, AS COLLATERAL AGENT 2016-11-17 US disclosed
US-20120208819-A1 HETEROCYCLIC COMPOUNDS USEFUL AS PDK1 INHIBITORS OXFORD FINANCE LLC, AS COLLATERAL AGENT 2012-08-16 US disclosed
US-8088766-B2 Cyanoguanidines and cyanoamidines as ErbB2 and EGFR inhibitors ARRAY BIOPHARMA INC. (US) 2012-01-03 US disclosed
US-20100331348-A1 TROPANE DERIVATIVES USEFUL AS PESTICIDES SYNGENTA CROP PROTECTION, INC. (US) 2010-12-30 US disclosed
US-7488823-B2 Cyanoguanidines and cyanoamidines as ErbB2 and EGFR inhibitors ARRAY BIOPHARMA, INC. (US) 2009-02-10 US disclosed
US-20090012290-A1 CYANOGUANIDINES AND CYANOAMIDINES AS ERBB2 AND EGFR INHIBITORS ARRAY BIOPHARMA, INC. (US) 2009-01-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120208819-A1 HETEROCYCLIC COMPOUNDS USEFUL AS PDK1 INHIBITORS PDK1, PDK2, PDK3 HTR1A 4799/4885HTR2A 4784/4885HTR7 4729/4885
US-20090012290-A1 CYANOGUANIDINES AND CYANOAMIDINES AS ERBB2 AND EGFR INHIBITORS ERBB2, GRB2, EGFR HTR1A 2378/4885HTR2A 717/4885HTR7 1957/4885
US-20100331348-A1 TROPANE DERIVATIVES USEFUL AS PESTICIDES DDT, ACHE, TPM3 HTR1A 459/4885HTR2A 963/4885HTR7 1866/4885
US-10030016-B2 Heterocyclic compounds useful as PDK1 inhibitors PDK1, PDK2, PDK3 HTR1A 4799/4885HTR2A 4784/4885HTR7 4729/4885
US-20160331756-A1 HETEROCYCLIC COMPOUNDS USEFUL AS PDK1 INHIBITORS PDK1, PDK2, PDK3 HTR1A 4799/4885HTR2A 4784/4885HTR7 4729/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.